Ablative Procedures of the Peripheral Nerves to Treat Pain
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Iowa Policy 07.01.73 alerts
Get alerted when Policy 07.01.73 changes without checking for updates manually.
Monitor payer policy activity
Clinical coverage and evidence review of peripheral nerve ablative procedures (radiofrequency ablation, cryoneurolysis/cryoablation, and chemical neurolysis) for treatment of various non-spinal pain syndromes; intended for Blue Cross Blue Shield - Iowa providers and medical reviewers.
No material clinical or coverage changes in this revision.
Coverage Criteria and Evidence Summary
inv-01: Evidence summaries by indication
Summary of evidence and conclusions for indications reviewed in this policy excerpt:
See RCTs, network meta-analyses, and extension studies through 24 months; evidence judged insufficient for definitive long-term benefit.
Short-term benefit demonstrated in some RCTs; durability and optimal technique uncertain.
Observational cohort (n=43) reported pain reduction up to 6 months but was noncomparative.
Single-center RCTs report significant short-term improvements but generalizability and durability remain uncertain.
Multiple small RCTs and case series included in reviews but methodological limitations predominate.
RCTs lacking; further research needed.
Some trials report longer duration of relief with PRF but samples are small.
RCT follow‑up limited to weeks–months and sample sizes small.
Some patients achieve relief but results inconsistent.
Trial required prior failed conservative therapy and >50% response to diagnostic spermatic cord block.
Additional adequately powered RCTs with longer follow‑up needed.
Subgroup analyses indicate heterogeneity related to concomitant analgesic methods.
inv-02: Investigational / Not medically necessary indications
The following uses of peripheral nerve ablation are considered investigational (not medically necessary) because evidence is insufficient to determine net health benefit:
Policy lists these indications as investigational.
inv-03: Evidence-based coverage criteria
Covered when ALL of the following evidence‑based considerations are met:
Derived from RCTs, systematic reviews and extension studies; diagnostic block response used in many trials and responder rate ~70% at 6 months for cooled RFA in some multicenter studies.
inv-04: Trial-based eligibility and selection
Evidence and selection criteria reflected in the cited randomized trials and extensions:
Trial-based selection criteria
- Conservative therapies: Documentation of prior conservative care (physical therapy, analgesics stable for 2 months, and prior intra‑articular steroid or viscosupplementation) was required in trials.stable for 2 months for oral analgesics
Per trial enrollment criteria.
- Diagnostic block response: At least 50% reduction in pain with anesthetic injection to targeted genicular branches was used as an inclusion criterion in several trials.>=50% pain reduction
Used in cooled RFA pilot and other trial protocols.
inv-05: Evidence-based coverage considerations
Evidence and clinical‑context considerations extracted from the review:
Longer follow‑up (≥12 months) preferred for durability assessment.
Heterogeneous results across studies (Kapural, Wu et al. analyses).
Attrition in extension studies and limited long‑term blinded data.
Hayes reviews and RCTs summarized show limited durable benefit beyond early follow‑up.
inv-06: Evidence synthesis
Findings from systematic reviews and trials summarizing efficacy and limitations:
Extension/longer‑term data show attrition and variable sustained responder rates.
Observed in cryoneurolysis and some RFA trials.
Repeat treatment benefit and optimal technique unresolved.
inv-07: Contextual coverage criteria
Consider ablative peripheral nerve procedures when ALL of the following contextual items are present:
Conservative therapies expected per guideline and trial comparators.
RFA effects often transient; longer follow‑up recommended.
Evidence varies by modality and indication.
inv-08: Coverage considerations / procedural candidacy
Evidence‑based considerations for procedural candidacy and documentation expectations:
Consistent with study comparators and guideline expectations.
Used in cooled RFA pilot and several trials for target confirmation.
Per trial follow‑up recommendations and evidence‑quality considerations.
inv-09: Implied medical necessity criteria for peripheral nerve ablation
Covered when ALL of the following are met (implied from trial selection and clinical context):
Implied from study inclusion criteria and reporting standards rather than explicit payer rule in this excerpt.
inv-10: Evidence-based considerations
Evidence summaries and considerations for select peripheral indications:
Makharita (2015) and Kastler (2012) provide trial data but sample sizes limit generalizability.
Larger, longer RCTs needed to establish durable benefit.
Policy flags lack of data across multiple indications.
inv-11: Evidence-based coverage statements
Summary of coverage‑relevant evidence and implications for selected indications:
Current evidence insufficient for definitive coverage conclusions.
No peer‑reviewed data available in the review.
Insufficient evidence for routine coverage.
RCTs needed.
inv-12: Evidence summaries by indication
Evidence summaries and applicability for select neuropathic pain indications:
Promising short‑term evidence but durability and broader applicability uncertain.
No serious adverse events consistently reported in small trials.
No data available in the literature review.
inv-13: Evidence summaries
Findings from RCTs, systematic reviews, and observational studies relevant to procedural choices and outcomes:
Evidence includes one RCT and multiple observational studies; heterogeneity high.
Additional adequately powered RCTs with longer follow‑up needed.
inv-14: Coverage considerations and clinical criteria
Coverage considerations and clinical criteria derived from evidence and guideline statements:
Professional guidance and meta‑analytic signals support selective use but emphasize need for higher‑quality RCTs.
ACR/AAOS conditional recommendations referenced.
Technique and long‑term safety data variable; documentation expected.
This medical policy may not apply to Federal Employee Program (FEP) members; benefit determinations for FEP participants are made separately by the Federal Employee Program and should be verified with the member's plan administrator.
The policy explicitly identifies the listed peripheral nerve ablation indications as investigational. Uses enumerated in the policy (for example, chronic knee or hip osteoarthritis, chronic orchialgia, chronic shoulder pain, inguinal and intercostal neuralgias, peripheral neuromas, plantar fasciitis, postherpetic neuralgia, and perioperative management for pectus/Nuss procedures) are considered investigational because available evidence is insufficient to determine net health benefit.
Procedures such as radiofrequency ablation are described in this document as symptomatic treatments rather than disease‑modifying or curative for osteoarthritis; interventions intended to alter the underlying disease course of OA are outside the scope of RFA's therapeutic intent as discussed in the evidence review.
Many randomized trials applied trial‑level selection criteria that required demonstration of a positive response to diagnostic anesthetic nerve block before enrollment; studies that did not select by diagnostic block or excluded patients without such a response limit applicability of trial results to patients without documented block response.
For cryoneurolysis using the iovera system, systematic reviews and evolving evidence reviews did not identify comparative studies against established standard‑of‑care alternatives for some knee OA contexts; available studies are heterogeneous and of variable quality, so the comparative effectiveness versus standard care remains uncertain.
The evidence base did not include studies evaluating the clinical benefit of repeat iovera (cryoanalgesia) treatments for knee osteoarthritis; durability and optimal retreatment timing for repeat cryoneurolysis are not established.
The review excluded or downgraded studies lacking methodologically credible designs (for example, single‑arm reports without standardized pre/post outcome measures or short follow‑up); procedures reported only in uncontrolled series or case reports therefore do not provide adequate evidence to establish effectiveness.
Evidence for ablative procedures in hip osteoarthritis is limited principally to small nonrandomized studies and short follow‑up; when evidence is restricted to these designs, the procedure should be considered investigational until corroborated by larger randomized trials with longer observation.
No peer‑reviewed studies were identified for chemical neurolysis (phenol, alcohol, glycerol) applied to chronic shoulder pain, and similarly none were identified for intercostal neuralgia in the literature review; therefore chemical neurolysis is unsupported by published studies for these indications.
A systematic review of the literature did not find published peer‑reviewed studies of chemical neurolysis for chronic inguinal neuralgia; absence of primary studies means the technique is unsupported by evidence for this indication.
The review identified no published studies of chemical neurolysis (alcohol, phenol, glycerol) for plantar fasciitis or for treatment of peripheral neuromas; these indications are therefore not supported by peer‑reviewed evidence.
No peer‑reviewed studies were found evaluating chemical neurolysis for chronic orchialgia or for postherpetic neuralgia; in the absence of published evidence, chemical neurolysis is unsupported for these indications.
Because many studies across indications were of low methodological quality, heterogeneous in design and outcomes, and limited in randomized controlled evidence, the authors recommend that well‑designed randomized trials with adequate sample sizes and longer follow‑up are needed to resolve uncertainties and establish effectiveness.
Caution is advised for pediatric application of intraoperative cryoablation (eg, in adolescents undergoing Nuss procedure) because existing evidence is limited; the document highlights the need for larger confirmatory studies before broadly extrapolating safety conclusions to children.
The references section does not include explicit statements excluding non‑medical‑necessity content; it lists the cited literature supporting the evidence review and does not add separate exclusionary language beyond the policy text.
Across the peripheral indications reviewed (including knee chemical neurolysis, hip RFA/chemical neurolysis, shoulder RFA, intercostal and inguinal neuralgias, plantar fasciitis, peripheral neuromas, orchialgia, and postherpetic neuralgia), the body of evidence is generally insufficient to conclude consistent, durable improvements in pain and function for most procedures; where randomized data exist they are often small, short‑term, or heterogeneous in methods, limiting definitive coverage conclusions.
The policy restates the enumerated investigational uses, which include: chronic knee and hip osteoarthritis (pre‑, post‑, or instead of joint replacement), chronic orchialgia, chronic shoulder pain, inguinal and intercostal neuralgias, peripheral neuromas, plantar fasciitis, postherpetic neuralgia, and perioperative/intraoperative/postoperative pain management related to pectus (Nuss) procedures.
When requests are considered for ablative procedures, documentation should include a history of prior conservative management (for example, physical therapy, analgesics, and, where applicable, intra‑articular injections), as well as quantifiable baseline pain and function measures (eg, VAS/NRS, WOMAC, KOOS) and a plan for follow‑up outcome assessment to demonstrate treatment effect.
Durability evidence is limited for several procedures described in the review; when longer‑term outcomes or randomized controlled evidence are absent, the document states these procedures may be considered investigational because sustained clinical benefit has not been established.
For chemical neurolysis in knee osteoarthritis, current data are limited to small cohorts and noncomparative series (for example, the 7% glycerinated phenol cohort), and the policy calls for larger randomized controlled trials with longer follow‑up to establish efficacy and safety before routine adoption.
Radiofrequency ablation and chemical neurolysis modalities that lack adequately powered randomized controlled trial evidence or only report short‑term outcomes should be considered not established for durable clinical benefit until higher‑quality randomized evidence with longer follow‑up is available.
For intercostal neuralgia, the available evidence consists primarily of small case series and reports; randomized trials are lacking and the evidence is insufficient to conclude efficacy for RFA in this condition.
The literature search did not identify peer‑reviewed studies supporting chemical neurolysis for inguinal neuralgia; therefore chemical neurolysis is unsupported for this indication.
Procedures reported only in uncontrolled single‑arm series, case reports, or small case series, or those with nonstandardized outcomes, inconsistent technical descriptions, or short follow‑up should be considered investigational until adequate randomized controlled evidence and standardized outcome reporting are available.
Overall, the evidence across many peripheral indications is insufficient to form definitive conclusions about long‑term clinical benefit and safety; where randomized data exist they are often short‑term or heterogeneous, and many indications lack controlled trials entirely.
The references section contains the citation list supporting the evidence synthesis; it does not include separate non‑medical‑necessity statements beyond the policy's investigational and not‑medically‑necessary designations.
Coding and Regulatory References
| No codes listed |
| See Codes table | Procedure and billing codes referenced in the policy's Codes table |
| K163461 | 510(k) for COOLIEF cooled radiofrequency probe |
| iOVERA system (Myoscience, Inc.) | Device/system referenced for cryoneurolysis/cryoablation |
Prior Authorization, Documentation, and Billing Actions
Prior Authorization May Be Required
Prior authorization may be required — verify member benefits and obtain prior approval when required. Refer to the payer authorization table and Codes table for applicable prior approval requirements and billing/coding references.
- Obtain prior approval when the member's contract requires it.
- Reference the payer Authorization Table and procedure Codes table for specific code-level prior approval guidance.
Prior Conservative Therapy Documentation
Document prior conservative therapy attempts and selection criteria before requesting authorization. Conservative therapies are the usual comparator and are expected prior to ablative procedures.
- Conservative measures: analgesics, physical therapy, weight loss, activity modification, assistive devices, NSAIDs, topical agents, intra‑articular injections (steroid, viscosupplementation) as appropriate.
- Document duration and response to prior therapies and reason for failure or intolerance.
Authorization: Document Conservative Care and Diagnostic Block Response
When authorization is requested, include documentation of prior conservative care and diagnostic block response when used to select patients (e.g., ≥50% pain reduction with diagnostic genicular or spermatic cord block). Also supply baseline measures (BMI, VAS/NRS, WOMAC, KOOS, SF-12/36) and expected benefit.
- Document diagnostic block response when used for selection (typically ≥50% reduction).
- Provide baseline and anticipated post-procedure outcome measures (pain scores and functional scales).
- Include BMI and duration/stability of analgesic regimens where applicable.
Prior Authorization Expectation
Prior authorization expectation: because evidence is limited or heterogeneous for many ablative and chemical neurolysis indications, prior approval reviews may request detailed trial documentation of conservative care, diagnostic block responses, baseline/outcome measures, and rationale for patient selection.
- Preparedness to supply homogenous clinical population data and standardized pre/post measures.
- Expectation that reviewers may request additional evidence when durability or comparative benefit is unclear.
Prior Authorization: Patient Selection and Documentation
Patient selection and documentation: authorization requests should demonstrate appropriate selection (failed conservative therapy, documented baseline pain and function, diagnostic block response when applicable) and a homogeneous clinical population for the indication.
- Required elements: indication, targeted nerve(s), prior treatments tried and failed, baseline pain (VAS/NRS) and functional scores.
- When used preoperatively (eg, cryoneurolysis prior to TKA), include operative plan and anticipated benefit.
Prior Conservative Therapy and Baseline Pain Required
For peripheral ablative procedures, prior conservative therapy and baseline pain/function documentation are required. Provide quantifiable pre- and post-treatment measures and duration of prior conservative trials to support medical necessity.
- Include validated scales: VAS/NRS, WOMAC, Oxford Knee Score, KOOS, LKS, AOFAS, SF-12/36 as applicable.
- Specify duration of conservative therapy and details of interventions (PT, medications, injections).
Outcome and Prior Treatment Documentation
Outcome and prior treatment documentation should include baseline pain scores, standardized functional measures, documentation of prior therapies and their durations, and follow-up outcome assessments to demonstrate clinical benefit and durability.
- Pre- and post-treatment VAS/NRS at defined timepoints (immediate, 1 month, 6 months, 12 months when available).
- Functional outcome measures (WOMAC, KOOS, Oxford Knee Score, AOFAS, SF‑12/36) and opioid consumption where relevant.
- For perioperative uses, include perioperative opioid use, length of stay, and discharge criteria.
Prior Authorization — Require Conservative Therapy Failure and Indication Justification
Prior authorization for investigational indications will typically require demonstration of conservative therapy failure and justification of indication; investigational procedures may be denied if not a covered benefit or evidence is insufficient.
- If indication is listed as investigational in policy, prior approval alone may not confer coverage — verify member benefits.
- Provide clear justification for use when conservative therapies have failed and alternative options are limited.
Preauthorization: Supply Indication and Expected Benefit
Preauthorization supply: when requesting preauthorization, supply the clinical indication, targeted procedure, anticipated benefit, and supporting documentation (prior therapies, diagnostic block response, baseline/outcome measures).
- Include expected timeframe for benefit and any planned perioperative analgesia strategy.
- Attach relevant operative/procedure plan when used in perioperative settings (eg, Nuss, TKA).
Benefit / Exclusion Risk
Benefit/exclusion risk: benefit determinations depend on the member's contract. Services not covered by the contract or listed as investigational may be denied even if prior authorization is requested.
- Verify member benefits at time of service; exclusions, limitations, or exceptions may apply.
- Investigational categorizations in this policy indicate that payment is unlikely under standard benefits.
Conservative Treatment and Selection Criteria
Conservative treatment and selection criteria: conservative therapies are expected before ablation. Documentation should show trials of standard therapies (medications, PT, injections) and reasons for proceeding to ablative treatment.
- Document specific conservative treatments attempted, duration, and response.
- When step therapy is relevant, attempt standard therapies first and document rationale for escalation.
Evidence Limitations May Trigger Denial
Evidence limitations may trigger denial: heterogeneity of studies, short follow-up, small sample sizes, and lack of blinding or credible methodology increase the risk that requests will be denied.
- Be prepared to supply longer-term outcome data and robust standardized measures when available.
- Trials with small samples, short follow-up, or missing comparator data are less persuasive for coverage.
Evidence Uncertainty May Lead to Denial
Evidence uncertainty may lead to denial: when the net clinical benefit is unclear, reviewers may determine the service is not medically necessary or is investigational and not covered.
- This is especially relevant for chemical neurolysis indications where evidence is lacking for many conditions.
Evidence / Documentation Insufficiency
Evidence and documentation insufficiency: missing quantifiable pre/post measures, absent diagnostic block response, or incomplete prior conservative therapy records may lead to denial of authorization or claim adjudication.
- Ensure inclusion of baseline and follow-up pain/function scores, diagnostic block results, and a clear history of prior therapies.
Denial Risk From Missing Pre-procedure Criteria
Denial risk from missing pre-procedure criteria: lack of documented diagnostic block response (when used) or failure to document conservative therapy attempts and baseline measures can result in denial.
- If diagnostic blocks are part of selection criteria, document ≥50% pain relief and timing relative to the procedure.
- Document why conservative options were inadequate or inappropriate.
Chemical Neurolysis Evidentiary Risk
Chemical neurolysis evidentiary risk: for many indications (hip, intercostal, orchialgia, plantar fasciitis, peripheral neuromas, PHN, shoulder) published evidence for chemical neurolysis is lacking; requests for chemical neurolysis are likely to face denial absent strong supporting data.
- No randomized trials identified for chemical neurolysis for multiple peripheral indications; include high-quality supportive evidence if available.
Evidence Quality Concern
Evidence quality concern: heterogeneity, low methodological quality, and limited sample sizes in the literature raise concern about reliability of effect estimates and may lead to noncoverage decisions.
- Provide higher-quality, longer-duration data and standardized outcome reporting to mitigate evidence-quality concerns.
No Denial Criteria in References
No denial criteria are provided in the References section of this policy; consult the policy body and payer-specific benefit language for coverage determinations.
- References list does not specify authorization or denial rules; use policy content and contract language for determinations.
Prior Approval and Coding Reference
Prior approval and coding reference: obtain prior approval per payer tables and include relevant procedure and diagnosis codes in the submission.
- Attach pertinent CPT/HCPCS/ICD-10 codes and clinical documentation to the prior authorization request.
- Refer to the Codes table for code-level guidance.
Document Baseline and Follow-up Quantifiable Outcomes
Document baseline and follow-up quantifiable outcomes: include pre- and post-treatment pain scores and validated functional measures at specified follow-up intervals to support claims of efficacy and durability.
- Typical follow-up intervals: immediate (procedural success), 1 month, 3–6 months, and 12 months to evaluate durability.
- Include opioid consumption and other objective perioperative measures when applicable.
Required Clinical Documentation
Required clinical documentation: authorization and retrospective review should include indication, targeted nerve(s), procedure details, prior conservative treatments, diagnostic block(s) and response, baseline pain/function measures, BMI where relevant, and expected benefit.
- Procedure details: device type, nerves targeted, number of cycles/lesions, imaging/guidance used.
- Include dates and providers for prior treatments and diagnostic blocks.
Required Clinical Outcome Documentation
Required clinical outcome documentation: include standardized pre/post measures and duration of prior conservative therapy; for perioperative uses include perioperative opioid use, LOS, and complications.
- Pre/post standardized measures (VAS/NRS, WOMAC, KOOS, Oxford Knee Score, AOFAS, SF‑12/36) with dates.
- Perioperative items: total opioid MME, LOS, discharge criteria, and adverse events.
Required Outcome Documentation
Required outcome documentation: provide baseline and post-treatment validated measures and follow-up to demonstrate benefit and durability; incomplete outcomes data weakens the authorization case.
- Report changes with means, standard deviations, and relevant p-values when available.
- For observational registry or retrospective studies submitted as support, provide demographics, follow-up duration, and complication rates.
Pain Scores and Follow-up Documentation
Pain scores and follow-up documentation: include immediate and longer-term pain scores (VAS/NRS) and functional assessments at predefined intervals to support clinical effectiveness claims.
- Immediate procedural success and longer-term assessments at 1, 3, 6, and 12 months where available.
- Document any repeat procedures and their timing.
Pain Measurement and Follow-up Documentation
Pain measurement and follow-up documentation for durability: supply baseline and follow-up assessments to support durability of response; short follow-up may be insufficient for coverage of denervation therapies.
- Durability expectations: initial procedural success within days and at least 6–12 months follow-up to assess longer-term benefit.
Suggested Documentation for Perioperative Pain Management
Suggested documentation for perioperative pain management: when used pre/intra/postoperatively (eg, cryoablation for TKA or Nuss), include operative report, analgesia plan, perioperative opioid consumption, length of stay, and discharge criteria.
- Provide inpatient and outpatient opioid MME, LOS, complications, and functional recovery measures.
- Include protocolized perioperative analgesia elements (nerve blocks, multimodal meds) to contextualize outcomes.
Consideration of Nonsurgical Modalities
Consideration of nonsurgical modalities: document trials of nonsurgical options (exercise, weight loss, PT, medications, injections) and rationale for escalation to ablative therapies.
- Describe duration and response to each nonsurgical modality.
- If step therapy applies, document attempts and reasons for not completing or failing those steps.
Conservative Therapy Expected Prior to Ablative Procedures
Conservative therapy expected prior to ablative procedures: trials of medications, physical therapy, and injections are expected; document failure or intolerance before proceeding to ablation.
- Record specific therapies tried, dates, providers, and objective response.
- When applicable, document contraindications to further conservative care.
Step Therapy — Attempt Standard Therapies First
Step therapy — attempt standard therapies first: when applicable, step therapy should be followed with documentation of each step and rationale for escalation to ablative interventions.
- Document dates and outcomes of each step-therapy element (eg, NSAIDs → PT → injections).
Conservative Therapy Prerequisites
Conservative therapy prerequisites: authorization reviewers expect documentation of relevant conservative measures (NSAIDs, antidepressants for neuropathic pain, PT, injections) and their duration prior to approving ablative procedures.
- For neuropathic conditions (eg, PHN, orchialgia), document trials of guideline‑recommended pharmacotherapies (eg, TCAs, gabapentinoids) and outcomes.
Comparative Context
Comparative context: many studies compared ablation or cryoablation to standard analgesic pathways (eg, thoracic epidural for Nuss procedure); when submitting evidence, provide comparative data and context versus standard of care.
- When available, include comparative outcomes such as LOS, opioid consumption, pain scores, and complication rates versus standard approaches.
Conservative Therapy Expected Before Ablation
Conservative therapy expected before ablation: in general, guideline and policy context favor a conservative‑first approach; document failure of conservative management and rationale for ablation.
- Ensure clear timeline from conservative therapies to diagnostic blocks to ablative intervention in the record.
Background and Definitions
Background: Ablative peripheral nerve techniques summarized in this review include radiofrequency ablation (standard, cooled, pulsed), cryoneurolysis/cryoablation (eg, iovera), and chemical neurolysis (agents such as phenol, alcohol, glycerol). These interventions target peripheral sensory nerves to reduce pain from a variety of non‑spinal pain syndromes; evidence quality, sample sizes, and follow‑up duration vary substantially across indications.
Conservative Therapy and Prerequisites
inv-146: Conservative therapy expected before invasive ablation for OA
Document failure of conservative therapies as reflected in study populations; specific durations vary by indication and trial:
Policy and trials require documentation of failed conservative management; see indication‑specific trial criteria for details.
inv-147: Documentation of inadequate symptom relief from conservative measures is expected prior to RFA.
Documentation expectations prior to RFA or other ablative procedures:
Documentation supports alignment with trial eligibility and payer review expectations.
inv-148: Documented trial of conservative therapy required per trial criteria (stable for 2 months for oral analgesics)
Trial-specified conservative therapy requirements that informed enrollment criteria:
Reflects common RCT eligibility provisions.
inv-149: Must document prior conservative treatment attempts and rationale for proceeding to ablation
Clinical requirement summarized from study comparators and evidence selection:
Consistent with trial comparators and guideline recommendations.
inv-150: Placeholder conservative criteria
Operational expectation for documentation before ablative procedures:
Supports prior authorization and medical necessity review.
inv-151: Conservative therapies should be attempted and documented prior to ablative procedures
Expectation summarized from trial designs and guideline context:
Reflects standard-of-care comparators and trial prerequisites.
inv-152: Documented failure of conservative therapy is expected before ablative procedures, per study comparators and eligibility.
Expectation based on study comparators and inclusion criteria:
Trial comparators and professional guidelines support this requirement.
inv-155: Document failed conservative therapy prior to ablative procedures (>= 3-6 months)
Timing expectations derived from case series inclusion and trial context:
Duration expectations vary by indication and study.
inv-156: Documented failure or inadequate response to appropriate conservative therapies is expected prior to considering ablative procedures.
General expectation from evidence selection for prior management:
Consistent with study enrollment criteria across indications.
Frequency, Repeat Procedures, and Procedural Limits
Imaging and Procedural Guidance
Not Covered / Investigational Procedures
NOT COVERED: Chemical neurolysis for multiple peripheral indications (including shoulder pain, intercostal neuralgia, inguinal neuralgia, plantar fasciitis, peripheral neuromas, orchialgia, and postherpetic neuralgia) lacks peer‑reviewed published literature in the reviewed evidence and is therefore considered not supported by adequate evidence in this policy.
NOT COVERED: Radiofrequency ablation, cryoneurolysis, and chemical neurolysis are listed as investigational for the enumerated indications in this policy (see policy investigational list); these modalities are therefore not established as medically necessary for those uses in the absence of stronger evidence.
NOT COVERED: Restatement — the policy lists multiple peripheral pain conditions for which ablative procedures are considered investigational; these listed uses should be treated as not covered absent contract language to the contrary.
NOT COVERED: Comparators such as platelet‑rich plasma or single intra‑articular injections are noted in trial contexts but are not established standard comparators for demonstrating durable superiority of ablation techniques; absence of high‑quality comparative data limits coverage for ablation when used in lieu of well‑established therapies.
NOT COVERED: Procedures without adequate randomized evidence or with only low‑quality case‑series data and inconsistent outcome measures may be determined not covered or investigational until higher quality evidence is available.
NOT COVERED: Interventions lacking adequate controlled evidence or without standardized outcome documentation (for example, some chemical neurolysis approaches reported only in case series) are not supported for routine coverage.
NOT COVERED: Chemical neurolysis for inguinal neuralgia is explicitly unsupported due to lack of peer‑reviewed studies and would be considered investigational.
Policy Revision History
Original effective date of the policy 'Ablative Procedures of the Peripheral Nerves to Treat Pain' established.
Hayes annual evidence review of the iovera cryoneurolysis system completed (December 2024 referenced in document).
Policy review date noted (November 2025) per document header metadata.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.